1. Volume 4, Issue 5, Pages 408-411 (June 2018)
Vismodegib-resistant basal cell carcinomas in basal cell nevus syndrome: Clinical approach and genetic analysis 
Kelly A.E. Sinx, MD, Guido M.J.M. Roemen, BASc, Virrie van Zutven, BSc, Renske Janssen, BASc, Ernst-Jan M. Speel, PhD, Peter M. Steijlen, MD, PhD, Michel van Geel, PhD, Klara Mosterd, MD, PhD 
JAAD Case Reports 
Volume 4, Issue 5, Pages (June 2018)
DOI: /j.jdcr
Copyright © 2017 American Academy of Dermatology, Inc. Terms and Conditions

2. Fig 1
BCNS patient. A, Before starting vismodegib. B, Clearance after 3 months of vismodegib treatment. C, BCC redevelopment (resistance).
JAAD Case Reports 2018 4, DOI: ( /j.jdcr )
Copyright © 2017 American Academy of Dermatology, Inc. Terms and Conditions